You are here

Article info

Article menu

Download PDFPDF

Editorial
Pirfenidone for IPF: pro/con debate; the ‘con’ viewpoint
Free

Authors

  • Ganesh Raghu Division of Pulmonary & Critical Care Medicine, University of Washington (UW), Scleroderma Clinic, UW Medical Center, Seattle, Washington, USA PubMed articlesGoogle scholar articles
  • David R Thickett Centre for Translational Inflammation and Fibrosis Research, School of Clinical and Experimental Medicine, University of Birmingham, UK PubMed articlesGoogle scholar articles
  1. Correspondence to Dr David Thickett, Centre for Translational Inflammation and Fibrosis Research, School of Clinical and Experimental Medicine, University of Birmingham, UK; d.thickett{at}bham.ac.uk
View Full Text

Citation

Raghu G, Thickett DR
Pirfenidone for IPF: pro/con debate; the ‘con’ viewpoint
Thorax 2013;68:605-608.

Publication history

  • First published March 5, 2013.
Online issue publication 
September 01, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions